Research programme: TRPV1 receptor antagonists - Renovis/PfizerAlternative Names: TRPV1 antagonists - Renovis/Pfizer; Vanilloid receptor antagonists - Renovis/Pfizer
Latest Information Update: 03 Apr 2013
At a glance
- Originator Pfizer; Renovis
- Developer Evotec AG; Pfizer
- Class Small molecules
- Mechanism of Action TRPV1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Pain; Urinary incontinence